Biological plausibility persuaded the panel; direct human evidence remained absent.
KPV’s official-record case is primarily mechanistic and nonclinical. FDA said it found no human administration or exposure data by any route.
FDA staff recommended against both forms; PCAC voted favorably on both form-level questions.
FDA reviewed preclinical anti-inflammatory and wound-related evidence and a cadaver-skin permeability study. That is a legitimate research signal, but it remains indirect.
FDA briefing pp. 19–23The key evidentiary break is not simply the absence of a large trial: FDA said it found no human administration or exposure data by any route.
FDA briefing pp. 25–27The committee outcome belongs beside the evidence record—not on top of it. A favorable advisory vote describes the panel’s recommendation on compounding eligibility; it does not erase FDA’s characterization, route-match or human-evidence concerns.
These are attributed testimony arguments, not PeptideBase endorsements. Each one is paired with the most relevant FDA answer and an explicit assessment of what the evidence can—and cannot—carry.
Only named speaker moments reconciled against a word-timestamped machine transcript of the official recording appear here. The method is two-pass transcript reconciliation: both passes read that same transcript, so this is not audio review and not independent primary-source confirmation. Where the two passes disagreed about who was speaking, the moment was withheld rather than published. Statements remain attributed arguments unless the underlying evidence was independently established from a named source outside the hearing record, and each moment carries its own disclosed limitations.
Board-certified urologist, private practice, Indianapolis
Verify credentialsTatem presented KPV as the three-amino-acid end fragment of alpha-MSH and described NF-κB signalling, PEPT1 transport, corneal-healing and anti-MRSA findings, plus a phase 2A programme for the related KDPT. He offered that work as a rationale for clinical interest, not as a human treatment result for KPV itself.
President and Executive Director, Center for Science in the Public Interest; former FDA Associate Commissioner
Verify credentialsLurie said CSPI opposed adding all seven substances, for three reasons: that listing would be inconsistent with FDA’s own compounding standards, that compounded products pose distinct consumer risks, and that listing would remove incentives to develop products through the standard drug-approval pathway.
Laboratory and animal findings can support biological plausibility. No human-administration result for the nominated KPV forms, routes and uses was established in the record used for this review.
FDA found a lack of evidence to evaluate effectiveness for the nominated uses and a lack of clinical and nonclinical safety information.
FDA Day 1 presentation · 06:12:25The biology explains why KPV merits research. It does not establish a safe human dose, a route-specific safety profile or clinical benefit.
The favorable majority appears to have treated preclinical plausibility and pharmacy controls as enough to recommend a pathway. FDA treated the absence of direct human exposure, effectiveness and safety data as unresolved under the listing criteria.
Editorial inference from the hearing record—not an attributed rationale for every voterThese are recurring propositions in the wider peptide discussion, not attributed speaker quotations.
FDA said the nomination contained no clinical studies and FDA identified no human exposure data for KPV by any route.
Biological origin or relationship to another peptide does not substitute for exposure, pharmacokinetic, immunogenicity or dose-ranging evidence for the exact compounded substance.
FDA identified an in-vitro human-cadaver-skin study reporting low permeability; penetration increased with enhancement techniques.
An in-vitro cadaver-skin result does not establish clinical delivery, effectiveness or systemic safety in living patients.
“Absent” means FDA said it did not identify that evidence within this evaluation. It is not a universal claim that no evidence exists anywhere.
| Evidence question | Status | FDA-record summary | Locator |
|---|---|---|---|
| Human clinical evidence | absent | FDA-record summaryFDA said it identified no clinical studies or human exposure data for any route. | LocatorBriefing pp. 25–27 |
| Nonclinical evidence | indirect | FDA-record summaryMechanistic, cell and animal findings were reviewed, but FDA found them inadequate to evaluate the nominated clinical uses. | LocatorBriefing pp. 19–24 |
| Exact-form match | limited | FDA-record summaryThe evidence did not establish a complete free-base-versus-acetate clinical record. | LocatorBriefing pp. 6–16 |
| Nominated-route match | absent | FDA-record summaryThe nominated route was topical; FDA identified no human administration data. | LocatorBriefing pp. 6, 16, 25–27 |
| Evaluated-use match | absent | FDA-record summaryFDA found no adequate human evidence for wound healing or inflammatory conditions. | LocatorBriefing pp. 19–22 |
| Product characterization | not well characterized | FDA-record summaryFDA concluded that “KPV (free base) is deemed to be not well-characterized from the physical and chemical characterization perspective”; the same conclusion is stated for KPV acetate. | LocatorBriefing pp. 7–16 |
| Human safety | absent | FDA-record summaryNo human exposure, clinical safety, immunogenicity or aggregation data were identified. | LocatorBriefing pp. 25–27 |
| Historical compounding use | limited | FDA-record summaryFDA found the extent of historical use in compounding unknown. | LocatorBriefing pp. 16–19 |
Qualitative evidence map · no numerical score · scoped to FDA’s July 2026 evaluation
A useful dossier should show the reader what evidence could materially strengthen or weaken the current read.
First-in-human safety, pharmacokinetic and dose-ranging evidence
Direct topical studies in the nominated wound and inflammatory uses
Validated reference standards and reproducible release specifications
The official record contains limited human evidence and substantial nonclinical literature, but the exact form, dosage form, route, duration and safety questions remain unresolved.
Open dossierDay 1The central technical issue is identity: FDA treated the seven-amino-acid TB-500 fragment as distinct from full-length thymosin beta-4 and found no direct human TB-500 evidence.
Open dossierFree newsletter
The Peptide Research Digest
Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.